hmj-38

HMJ-38 is a **quinazolinone derivative** and novel synthetic small molecule investigated for its anticancer activities. It acts primarily by **inhibiting tubulin polymerization**, which disrupts microtubule formation and leads to cell cycle arrest in the G2/M phase, autophagy, and caspase-mediated apoptosis in cancer cells, including oral, leukemia, and gemcitabine-resistant pancreatic cancer cells[1]. HMJ-38 also targets the **epidermal growth factor receptor (EGFR)**, inhibiting its kinase activity and downstream signaling in gemcitabine-resistant pancreatic cancer cells[1]. In non-cancerous cells like HUVECs, HMJ-38 provokes DNA damage via an **ROS-dependent pathway** and extrinsic ATM/p53-regulated apoptosis[3][5]. HMJ-38 also suppresses angiogenesis by blocking tube formation, endothelial migration, and microvessel growth via VEGF response disruption and induces apoptotic death in endothelial cells[3]. There are no reports of clinical trials for HMJ-38, and its development appears to be limited to preclinical research.

Other names

2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone